Do Pharmaceutical Mergers Harm Drug Innovation?

Business & Finance
Cover of the book Do Pharmaceutical Mergers Harm Drug Innovation? by Jan Schmidt, GRIN Verlag
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Jan Schmidt ISBN: 9783656962168
Publisher: GRIN Verlag Publication: May 15, 2015
Imprint: GRIN Verlag Language: English
Author: Jan Schmidt
ISBN: 9783656962168
Publisher: GRIN Verlag
Publication: May 15, 2015
Imprint: GRIN Verlag
Language: English

Master's Thesis from the year 2013 in the subject Business economics - Miscellaneous, grade: 8,5 (NL, äquivalent zu 1,2), Utrecht University (Law, Economics and Governance), course: Mergers & Akquisitions, language: English, abstract: The number and volume of pharmaceutical companies' mergers and acquisitions have reached exorbitant magnitudes in the last decade, with estimations of over 1,300 deals worth US$ 690 billion between 2000 and 2009.1 The biggest transaction, valued at US$ 66.7 billion2, occurred in 2009 when Pfizer bought Wyeth. The sheer dimension of transactions in this sector, being subject to significant public interest, poses questions about the motivations behind these deals, which are mostly believed to be countermeasures for patent expirations, as well as the impact on drug innovation. Even though, the regular object of interest regarding mergers is the shareholder value, in this specific case drug innovation is of particular interest as it does not only influence the future prospects of the pharmaceutical companies but also long term public health. Hence, the objective of this thesis is to discover what the impact of pharmaceutical mergers on R&D intensity and efficiency of the acquiring organization and on the pharmaceutical industry as a whole is.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Master's Thesis from the year 2013 in the subject Business economics - Miscellaneous, grade: 8,5 (NL, äquivalent zu 1,2), Utrecht University (Law, Economics and Governance), course: Mergers & Akquisitions, language: English, abstract: The number and volume of pharmaceutical companies' mergers and acquisitions have reached exorbitant magnitudes in the last decade, with estimations of over 1,300 deals worth US$ 690 billion between 2000 and 2009.1 The biggest transaction, valued at US$ 66.7 billion2, occurred in 2009 when Pfizer bought Wyeth. The sheer dimension of transactions in this sector, being subject to significant public interest, poses questions about the motivations behind these deals, which are mostly believed to be countermeasures for patent expirations, as well as the impact on drug innovation. Even though, the regular object of interest regarding mergers is the shareholder value, in this specific case drug innovation is of particular interest as it does not only influence the future prospects of the pharmaceutical companies but also long term public health. Hence, the objective of this thesis is to discover what the impact of pharmaceutical mergers on R&D intensity and efficiency of the acquiring organization and on the pharmaceutical industry as a whole is.

More books from GRIN Verlag

Cover of the book Die Öffentliche Wahrnehmung von Politik und die Rolle der Medien im politischen Prozess by Jan Schmidt
Cover of the book Unterrichtungspflichten bei Betriebsübergang by Jan Schmidt
Cover of the book Arthur Schopenhauers 'Über den Wahnsinn' in seinem Hauptwerk 'Die Welt als Wille und Vorstellung' by Jan Schmidt
Cover of the book Der Bildungsbegriff bei Wilhelm von Humboldt und seine Auswirkungen auf das deutsche Schulsystem by Jan Schmidt
Cover of the book Innovative Vergütungsmodelle im Top Management by Jan Schmidt
Cover of the book Von shishiwuai zu lishiwuai - Guifeng Zongmi, Chan und der ontologische Paradigmenwechsel in der Huayan-Schule by Jan Schmidt
Cover of the book Effizienzverlust durch rationalisierte Kommunikation by Jan Schmidt
Cover of the book Die Getriebemontage im JD-Werk Mannheim by Jan Schmidt
Cover of the book Gentrification: Gentrifier, Pioniere und Alteingesessene by Jan Schmidt
Cover of the book Reporting, Informationsmanagement und Datenverarbeitung im Real Estate Asset Management by Jan Schmidt
Cover of the book Anaerobic and anoxic experiments of waste water by Jan Schmidt
Cover of the book Business Model Innovation - Ein generischer Entwicklungsprozess mit dem Schwerpunkt Business Model Controlling by Jan Schmidt
Cover of the book Die Rolle des Staates bei der Minderung von Informationsasymmetrien by Jan Schmidt
Cover of the book Der Verzicht auf die Wahlrechtsreform by Jan Schmidt
Cover of the book Palliative Care und Soziale Arbeit by Jan Schmidt
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy